Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy

Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy

Globally, human immunodeficiency virus type 1 (HIV-1) infection is a major health burden for which successful therapeutic options are still being investigated. Challenges facing current drugs that are part of the established life-long antiretroviral therapy (ART) include toxicity, development of dru...

Full description

Bibliographic Details
Main Authors: Hager Mohamed, Theodore Gurrola, Rachel Berman, Mackenzie Collins, Ilker K. Sariyer, Michael R. Nonnemacher, Brian Wigdahl
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Immunology
Subjects:
antiretroviral drugs
CCR5Δ32
CCR5 monoclonal antibodies
CCR5 small molecule inhibitors
HIV-1 drug resistance
zinc finger nucleases
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.816515/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.816515/full

Similar Items